Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of PEG-Intron 1.5microg/Kg/Wk plus REBETOL vs PEG-Intron 1microg/kg/wk plus REBETOL vs PEGASYS 180microg/Wk plus COPEGUS in previously untreated adult subjects with chronic hepatitis C infected with genotype 1

Next Previous
X
Search
Trial Profile

Comparison of PEG-Intron 1.5microg/Kg/Wk plus REBETOL vs PEG-Intron 1microg/kg/wk plus REBETOL vs PEGASYS 180microg/Wk plus COPEGUS in previously untreated adult subjects with chronic hepatitis C infected with genotype 1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms IDEAL
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 03 Nov 2009 Actual patient number changed from 3070 to 4469 as reported by ClinicalTrials.gov.
    • 06 Aug 2009 Results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top